Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in the field of schizophrenia. In this educational program, these experts discuss the rationale for muscarinic receptor modulation, clinical data, and the use of xanomeline/trospium chloride, the recently approved therapy in this class for the management of schizophrenia.
This educational activity is an archive of the live symposium held on November 22, 2025.
Target Audience
This educational activity is directed toward psychiatrists who treat patients with a range of psychiatric disorders. Psychiatric nurse practitioners, psychiatric nurses, pharmacists, and other health care professionals interested in the treatment of patients with psychiatric disorders are invited to participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Identify the role of the cholinergic pathway in the pathophysiology of schizophrenia
- Assess clinical trial data for agents targeting muscarinic receptors for schizophrenia
Ilan Melnick, MD
Passageway Residence of Dade County
Miami, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Eisai, Idorsia, Indivior, Intra-Cellular Therapies, Janssen, Lilly, Lundbeck, Merck, Neurocrine Biosciences, Noven, Otsuka, Sage, Sunovion, Takeda, Teva, Vanda
Linda Collado, MD, DABPN, FAPA
Associate Program Director
Department of Psychiatry
Banyan Health Systems
Miami, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bristol Myers Squibb
Maria Collado, MD, FAPA
Clinical
Director
Adult Crisis
Stabilization Unit
Citrus Health
Network Inc.
Hialeah, FL
Disclosures: Maria Collado, MD, FAPA, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COIs for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here